艾迪药业：注射用ADB116获药物临床试验批准通知书

Core Viewpoint - The company and its subsidiary, Nanjing Nanda Pharmaceutical, have received approval from the National Medical Products Administration for clinical trials of a new drug, ADB116, aimed at treating acute ischemic stroke patients [1] Group 1: Drug Development - The approved drug, ADB116, is a high molecular weight urokinase preparation intended for thrombolytic therapy in acute ischemic stroke patients [1] - The company will conduct Phase I clinical trials based on further research as required by the approval notice [1] Group 2: Business Impact - If ADB116 is successfully approved for market launch, it will provide more treatment options for stroke patients [1] - The product line of the company will be significantly expanded, leading to a more comprehensive layout in the main business areas of anti-HIV and human-derived proteins [1] - The diversification of business and revenue sources will be enhanced [1]